img

Global Beta-Adrenoceptor Agonists Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Beta-Adrenoceptor Agonists Market Research Report 2024

Beta-adrenoceptor agonists (β-agonists) bind to the β-receptors on the smooth muscle tissues and cardiac tissues. They also have important actions in other tissues, especially bronchial smooth muscle, the liver, and kidneys. Beta-adrenoceptors usually bind to norepinephrine that is released by the sympathetic adrenergic nerves, and to circulating epinephrine. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
According to Mr Accuracy reports’s new survey, global Beta-Adrenoceptor Agonists market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Beta-Adrenoceptor Agonists market research.
Key manufacturers engaged in the Beta-Adrenoceptor Agonists industry include F. Hoffmann-La Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK plc, Novartis AG, Bayer AG and Lilly, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Beta-Adrenoceptor Agonists were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Beta-Adrenoceptor Agonists market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Beta-Adrenoceptor Agonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


F. Hoffmann-La Roche Ltd
Mylan NV
Teva Pharmaceutical Industries Ltd
Sanofi
Pfizer Inc
GSK plc
Novartis AG
Bayer AG
Lilly
Merck & Co., Inc
Sun Pharmaceutical Industries Ltd
Aurobindo Pharma
Lupin
Amneal Pharmaceuticals LLC
Eisai Co., Ltd
Segment by Type
β 1 Agonist
β 2 Agonists

Segment by Application


Asthma
Anaphylactic Shock
Severe Hypotension
Acute Heart Failure
Acute Renal Failure
Other

Consumption by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Beta-Adrenoceptor Agonists report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Beta-Adrenoceptor Agonists Market Overview
1.1 Product Overview and Scope of Beta-Adrenoceptor Agonists
1.2 Beta-Adrenoceptor Agonists Segment by Type
1.2.1 Global Beta-Adrenoceptor Agonists Market Value Comparison by Type (2024-2034)
1.2.2 β 1 Agonist
1.2.3 β 2 Agonists
1.3 Beta-Adrenoceptor Agonists Segment by Application
1.3.1 Global Beta-Adrenoceptor Agonists Market Value by Application: (2024-2034)
1.3.2 Asthma
1.3.3 Anaphylactic Shock
1.3.4 Severe Hypotension
1.3.5 Acute Heart Failure
1.3.6 Acute Renal Failure
1.3.7 Other
1.4 Global Beta-Adrenoceptor Agonists Market Size Estimates and Forecasts
1.4.1 Global Beta-Adrenoceptor Agonists Revenue 2018-2029
1.4.2 Global Beta-Adrenoceptor Agonists Sales 2018-2029
1.4.3 Global Beta-Adrenoceptor Agonists Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Beta-Adrenoceptor Agonists Market Competition by Manufacturers
2.1 Global Beta-Adrenoceptor Agonists Sales Market Share by Manufacturers (2018-2024)
2.2 Global Beta-Adrenoceptor Agonists Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Beta-Adrenoceptor Agonists Average Price by Manufacturers (2018-2024)
2.4 Global Beta-Adrenoceptor Agonists Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Beta-Adrenoceptor Agonists, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Beta-Adrenoceptor Agonists, Product Type & Application
2.7 Beta-Adrenoceptor Agonists Market Competitive Situation and Trends
2.7.1 Beta-Adrenoceptor Agonists Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Beta-Adrenoceptor Agonists Players Market Share by Revenue
2.7.3 Global Beta-Adrenoceptor Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Beta-Adrenoceptor Agonists Retrospective Market Scenario by Region
3.1 Global Beta-Adrenoceptor Agonists Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Beta-Adrenoceptor Agonists Global Beta-Adrenoceptor Agonists Sales by Region: 2018-2029
3.2.1 Global Beta-Adrenoceptor Agonists Sales by Region: 2018-2024
3.2.2 Global Beta-Adrenoceptor Agonists Sales by Region: 2024-2029
3.3 Global Beta-Adrenoceptor Agonists Global Beta-Adrenoceptor Agonists Revenue by Region: 2018-2029
3.3.1 Global Beta-Adrenoceptor Agonists Revenue by Region: 2018-2024
3.3.2 Global Beta-Adrenoceptor Agonists Revenue by Region: 2024-2029
3.4 North America Beta-Adrenoceptor Agonists Market Facts & Figures by Country
3.4.1 North America Beta-Adrenoceptor Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Beta-Adrenoceptor Agonists Sales by Country (2018-2029)
3.4.3 North America Beta-Adrenoceptor Agonists Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Beta-Adrenoceptor Agonists Market Facts & Figures by Country
3.5.1 Europe Beta-Adrenoceptor Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Beta-Adrenoceptor Agonists Sales by Country (2018-2029)
3.5.3 Europe Beta-Adrenoceptor Agonists Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Beta-Adrenoceptor Agonists Market Facts & Figures by Country
3.6.1 Asia Pacific Beta-Adrenoceptor Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Beta-Adrenoceptor Agonists Sales by Country (2018-2029)
3.6.3 Asia Pacific Beta-Adrenoceptor Agonists Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Beta-Adrenoceptor Agonists Market Facts & Figures by Country
3.7.1 Latin America Beta-Adrenoceptor Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Beta-Adrenoceptor Agonists Sales by Country (2018-2029)
3.7.3 Latin America Beta-Adrenoceptor Agonists Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Beta-Adrenoceptor Agonists Market Facts & Figures by Country
3.8.1 Middle East and Africa Beta-Adrenoceptor Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Beta-Adrenoceptor Agonists Sales by Country (2018-2029)
3.8.3 Middle East and Africa Beta-Adrenoceptor Agonists Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Beta-Adrenoceptor Agonists Sales by Type (2018-2029)
4.1.1 Global Beta-Adrenoceptor Agonists Sales by Type (2018-2024)
4.1.2 Global Beta-Adrenoceptor Agonists Sales by Type (2024-2029)
4.1.3 Global Beta-Adrenoceptor Agonists Sales Market Share by Type (2018-2029)
4.2 Global Beta-Adrenoceptor Agonists Revenue by Type (2018-2029)
4.2.1 Global Beta-Adrenoceptor Agonists Revenue by Type (2018-2024)
4.2.2 Global Beta-Adrenoceptor Agonists Revenue by Type (2024-2029)
4.2.3 Global Beta-Adrenoceptor Agonists Revenue Market Share by Type (2018-2029)
4.3 Global Beta-Adrenoceptor Agonists Price by Type (2018-2029)
5 Segment by Application
5.1 Global Beta-Adrenoceptor Agonists Sales by Application (2018-2029)
5.1.1 Global Beta-Adrenoceptor Agonists Sales by Application (2018-2024)
5.1.2 Global Beta-Adrenoceptor Agonists Sales by Application (2024-2029)
5.1.3 Global Beta-Adrenoceptor Agonists Sales Market Share by Application (2018-2029)
5.2 Global Beta-Adrenoceptor Agonists Revenue by Application (2018-2029)
5.2.1 Global Beta-Adrenoceptor Agonists Revenue by Application (2018-2024)
5.2.2 Global Beta-Adrenoceptor Agonists Revenue by Application (2024-2029)
5.2.3 Global Beta-Adrenoceptor Agonists Revenue Market Share by Application (2018-2029)
5.3 Global Beta-Adrenoceptor Agonists Price by Application (2018-2029)
6 Key Companies Profiled
6.1 F. Hoffmann-La Roche Ltd
6.1.1 F. Hoffmann-La Roche Ltd Corporation Information
6.1.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.1.3 F. Hoffmann-La Roche Ltd Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.1.4 F. Hoffmann-La Roche Ltd Beta-Adrenoceptor Agonists Product Portfolio
6.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.2 Mylan NV
6.2.1 Mylan NV Corporation Information
6.2.2 Mylan NV Description and Business Overview
6.2.3 Mylan NV Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Mylan NV Beta-Adrenoceptor Agonists Product Portfolio
6.2.5 Mylan NV Recent Developments/Updates
6.3 Teva Pharmaceutical Industries Ltd
6.3.1 Teva Pharmaceutical Industries Ltd Corporation Information
6.3.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.3.3 Teva Pharmaceutical Industries Ltd Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Teva Pharmaceutical Industries Ltd Beta-Adrenoceptor Agonists Product Portfolio
6.3.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Sanofi Beta-Adrenoceptor Agonists Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Pfizer Inc
6.5.1 Pfizer Inc Corporation Information
6.5.2 Pfizer Inc Description and Business Overview
6.5.3 Pfizer Inc Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Pfizer Inc Beta-Adrenoceptor Agonists Product Portfolio
6.5.5 Pfizer Inc Recent Developments/Updates
6.6 GSK plc
6.6.1 GSK plc Corporation Information
6.6.2 GSK plc Description and Business Overview
6.6.3 GSK plc Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.6.4 GSK plc Beta-Adrenoceptor Agonists Product Portfolio
6.6.5 GSK plc Recent Developments/Updates
6.7 Novartis AG
6.6.1 Novartis AG Corporation Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Novartis AG Beta-Adrenoceptor Agonists Product Portfolio
6.7.5 Novartis AG Recent Developments/Updates
6.8 Bayer AG
6.8.1 Bayer AG Corporation Information
6.8.2 Bayer AG Description and Business Overview
6.8.3 Bayer AG Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Bayer AG Beta-Adrenoceptor Agonists Product Portfolio
6.8.5 Bayer AG Recent Developments/Updates
6.9 Lilly
6.9.1 Lilly Corporation Information
6.9.2 Lilly Description and Business Overview
6.9.3 Lilly Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Lilly Beta-Adrenoceptor Agonists Product Portfolio
6.9.5 Lilly Recent Developments/Updates
6.10 Merck & Co., Inc
6.10.1 Merck & Co., Inc Corporation Information
6.10.2 Merck & Co., Inc Description and Business Overview
6.10.3 Merck & Co., Inc Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Merck & Co., Inc Beta-Adrenoceptor Agonists Product Portfolio
6.10.5 Merck & Co., Inc Recent Developments/Updates
6.11 Sun Pharmaceutical Industries Ltd
6.11.1 Sun Pharmaceutical Industries Ltd Corporation Information
6.11.2 Sun Pharmaceutical Industries Ltd Beta-Adrenoceptor Agonists Description and Business Overview
6.11.3 Sun Pharmaceutical Industries Ltd Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Sun Pharmaceutical Industries Ltd Beta-Adrenoceptor Agonists Product Portfolio
6.11.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
6.12 Aurobindo Pharma
6.12.1 Aurobindo Pharma Corporation Information
6.12.2 Aurobindo Pharma Beta-Adrenoceptor Agonists Description and Business Overview
6.12.3 Aurobindo Pharma Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Aurobindo Pharma Beta-Adrenoceptor Agonists Product Portfolio
6.12.5 Aurobindo Pharma Recent Developments/Updates
6.13 Lupin
6.13.1 Lupin Corporation Information
6.13.2 Lupin Beta-Adrenoceptor Agonists Description and Business Overview
6.13.3 Lupin Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Lupin Beta-Adrenoceptor Agonists Product Portfolio
6.13.5 Lupin Recent Developments/Updates
6.14 Amneal Pharmaceuticals LLC
6.14.1 Amneal Pharmaceuticals LLC Corporation Information
6.14.2 Amneal Pharmaceuticals LLC Beta-Adrenoceptor Agonists Description and Business Overview
6.14.3 Amneal Pharmaceuticals LLC Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Amneal Pharmaceuticals LLC Beta-Adrenoceptor Agonists Product Portfolio
6.14.5 Amneal Pharmaceuticals LLC Recent Developments/Updates
6.15 Eisai Co., Ltd
6.15.1 Eisai Co., Ltd Corporation Information
6.15.2 Eisai Co., Ltd Beta-Adrenoceptor Agonists Description and Business Overview
6.15.3 Eisai Co., Ltd Beta-Adrenoceptor Agonists Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Eisai Co., Ltd Beta-Adrenoceptor Agonists Product Portfolio
6.15.5 Eisai Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Beta-Adrenoceptor Agonists Industry Chain Analysis
7.2 Beta-Adrenoceptor Agonists Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Beta-Adrenoceptor Agonists Production Mode & Process
7.4 Beta-Adrenoceptor Agonists Sales and Marketing
7.4.1 Beta-Adrenoceptor Agonists Sales Channels
7.4.2 Beta-Adrenoceptor Agonists Distributors
7.5 Beta-Adrenoceptor Agonists Customers
8 Beta-Adrenoceptor Agonists Market Dynamics
8.1 Beta-Adrenoceptor Agonists Industry Trends
8.2 Beta-Adrenoceptor Agonists Market Drivers
8.3 Beta-Adrenoceptor Agonists Market Challenges
8.4 Beta-Adrenoceptor Agonists Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Beta-Adrenoceptor Agonists Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Beta-Adrenoceptor Agonists Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Beta-Adrenoceptor Agonists Market Competitive Situation by Manufacturers in 2022
Table 4. Global Beta-Adrenoceptor Agonists Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Beta-Adrenoceptor Agonists Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Beta-Adrenoceptor Agonists Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Beta-Adrenoceptor Agonists Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Beta-Adrenoceptor Agonists Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Beta-Adrenoceptor Agonists, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Beta-Adrenoceptor Agonists, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Beta-Adrenoceptor Agonists, Product Type & Application
Table 12. Global Key Manufacturers of Beta-Adrenoceptor Agonists, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Beta-Adrenoceptor Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Beta-Adrenoceptor Agonists as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Beta-Adrenoceptor Agonists Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Beta-Adrenoceptor Agonists Sales by Region (2018-2024) & (K Units)
Table 18. Global Beta-Adrenoceptor Agonists Sales Market Share by Region (2018-2024)
Table 19. Global Beta-Adrenoceptor Agonists Sales by Region (2024-2029) & (K Units)
Table 20. Global Beta-Adrenoceptor Agonists Sales Market Share by Region (2024-2029)
Table 21. Global Beta-Adrenoceptor Agonists Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Beta-Adrenoceptor Agonists Revenue Market Share by Region (2018-2024)
Table 23. Global Beta-Adrenoceptor Agonists Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Beta-Adrenoceptor Agonists Revenue Market Share by Region (2024-2029)
Table 25. North America Beta-Adrenoceptor Agonists Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Beta-Adrenoceptor Agonists Sales by Country (2018-2024) & (K Units)
Table 27. North America Beta-Adrenoceptor Agonists Sales by Country (2024-2029) & (K Units)
Table 28. North America Beta-Adrenoceptor Agonists Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Beta-Adrenoceptor Agonists Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Beta-Adrenoceptor Agonists Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Beta-Adrenoceptor Agonists Sales by Country (2018-2024) & (K Units)
Table 32. Europe Beta-Adrenoceptor Agonists Sales by Country (2024-2029) & (K Units)
Table 33. Europe Beta-Adrenoceptor Agonists Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Beta-Adrenoceptor Agonists Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Beta-Adrenoceptor Agonists Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Beta-Adrenoceptor Agonists Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Beta-Adrenoceptor Agonists Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Beta-Adrenoceptor Agonists Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Beta-Adrenoceptor Agonists Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Beta-Adrenoceptor Agonists Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Beta-Adrenoceptor Agonists Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Beta-Adrenoceptor Agonists Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Beta-Adrenoceptor Agonists Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Beta-Adrenoceptor Agonists Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Beta-Adrenoceptor Agonists Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Beta-Adrenoceptor Agonists Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Beta-Adrenoceptor Agonists Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Beta-Adrenoceptor Agonists Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Beta-Adrenoceptor Agonists Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Beta-Adrenoceptor Agonists Sales (K Units) by Type (2018-2024)
Table 51. Global Beta-Adrenoceptor Agonists Sales (K Units) by Type (2024-2029)
Table 52. Global Beta-Adrenoceptor Agonists Sales Market Share by Type (2018-2024)
Table 53. Global Beta-Adrenoceptor Agonists Sales Market Share by Type (2024-2029)
Table 54. Global Beta-Adrenoceptor Agonists Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Beta-Adrenoceptor Agonists Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Beta-Adrenoceptor Agonists Revenue Market Share by Type (2018-2024)
Table 57. Global Beta-Adrenoceptor Agonists Revenue Market Share by Type (2024-2029)
Table 58. Global Beta-Adrenoceptor Agonists Price (US$/Unit) by Type (2018-2024)
Table 59. Global Beta-Adrenoceptor Agonists Price (US$/Unit) by Type (2024-2029)
Table 60. Global Beta-Adrenoceptor Agonists Sales (K Units) by Application (2018-2024)
Table 61. Global Beta-Adrenoceptor Agonists Sales (K Units) by Application (2024-2029)
Table 62. Global Beta-Adrenoceptor Agonists Sales Market Share by Application (2018-2024)
Table 63. Global Beta-Adrenoceptor Agonists Sales Market Share by Application (2024-2029)
Table 64. Global Beta-Adrenoceptor Agonists Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Beta-Adrenoceptor Agonists Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Beta-Adrenoceptor Agonists Revenue Market Share by Application (2018-2024)
Table 67. Global Beta-Adrenoceptor Agonists Revenue Market Share by Application (2024-2029)
Table 68. Global Beta-Adrenoceptor Agonists Price (US$/Unit) by Application (2018-2024)
Table 69. Global Beta-Adrenoceptor Agonists Price (US$/Unit) by Application (2024-2029)
Table 70. F. Hoffmann-La Roche Ltd Corporation Information
Table 71. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 72. F. Hoffmann-La Roche Ltd Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. F. Hoffmann-La Roche Ltd Beta-Adrenoceptor Agonists Product
Table 74. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 75. Mylan NV Corporation Information
Table 76. Mylan NV Description and Business Overview
Table 77. Mylan NV Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. Mylan NV Beta-Adrenoceptor Agonists Product
Table 79. Mylan NV Recent Developments/Updates
Table 80. Teva Pharmaceutical Industries Ltd Corporation Information
Table 81. Teva Pharmaceutical Industries Ltd Description and Business Overview
Table 82. Teva Pharmaceutical Industries Ltd Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Teva Pharmaceutical Industries Ltd Beta-Adrenoceptor Agonists Product
Table 84. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
Table 85. Sanofi Corporation Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Sanofi Beta-Adrenoceptor Agonists Product
Table 89. Sanofi Recent Developments/Updates
Table 90. Pfizer Inc Corporation Information
Table 91. Pfizer Inc Description and Business Overview
Table 92. Pfizer Inc Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Pfizer Inc Beta-Adrenoceptor Agonists Product
Table 94. Pfizer Inc Recent Developments/Updates
Table 95. GSK plc Corporation Information
Table 96. GSK plc Description and Business Overview
Table 97. GSK plc Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. GSK plc Beta-Adrenoceptor Agonists Product
Table 99. GSK plc Recent Developments/Updates
Table 100. Novartis AG Corporation Information
Table 101. Novartis AG Description and Business Overview
Table 102. Novartis AG Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Novartis AG Beta-Adrenoceptor Agonists Product
Table 104. Novartis AG Recent Developments/Updates
Table 105. Bayer AG Corporation Information
Table 106. Bayer AG Description and Business Overview
Table 107. Bayer AG Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. Bayer AG Beta-Adrenoceptor Agonists Product
Table 109. Bayer AG Recent Developments/Updates
Table 110. Lilly Corporation Information
Table 111. Lilly Description and Business Overview
Table 112. Lilly Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Lilly Beta-Adrenoceptor Agonists Product
Table 114. Lilly Recent Developments/Updates
Table 115. Merck & Co., Inc Corporation Information
Table 116. Merck & Co., Inc Description and Business Overview
Table 117. Merck & Co., Inc Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Merck & Co., Inc Beta-Adrenoceptor Agonists Product
Table 119. Merck & Co., Inc Recent Developments/Updates
Table 120. Sun Pharmaceutical Industries Ltd Corporation Information
Table 121. Sun Pharmaceutical Industries Ltd Description and Business Overview
Table 122. Sun Pharmaceutical Industries Ltd Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Sun Pharmaceutical Industries Ltd Beta-Adrenoceptor Agonists Product
Table 124. Sun Pharmaceutical Industries Ltd Recent Developments/Updates
Table 125. Aurobindo Pharma Corporation Information
Table 126. Aurobindo Pharma Description and Business Overview
Table 127. Aurobindo Pharma Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. Aurobindo Pharma Beta-Adrenoceptor Agonists Product
Table 129. Aurobindo Pharma Recent Developments/Updates
Table 130. Lupin Corporation Information
Table 131. Lupin Description and Business Overview
Table 132. Lupin Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. Lupin Beta-Adrenoceptor Agonists Product
Table 134. Lupin Recent Developments/Updates
Table 135. Amneal Pharmaceuticals LLC Corporation Information
Table 136. Amneal Pharmaceuticals LLC Description and Business Overview
Table 137. Amneal Pharmaceuticals LLC Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. Amneal Pharmaceuticals LLC Beta-Adrenoceptor Agonists Product
Table 139. Amneal Pharmaceuticals LLC Recent Developments/Updates
Table 140. Eisai Co., Ltd Corporation Information
Table 141. Eisai Co., Ltd Description and Business Overview
Table 142. Eisai Co., Ltd Beta-Adrenoceptor Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 143. Eisai Co., Ltd Beta-Adrenoceptor Agonists Product
Table 144. Eisai Co., Ltd Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Beta-Adrenoceptor Agonists Distributors List
Table 148. Beta-Adrenoceptor Agonists Customers List
Table 149. Beta-Adrenoceptor Agonists Market Trends
Table 150. Beta-Adrenoceptor Agonists Market Drivers
Table 151. Beta-Adrenoceptor Agonists Market Challenges
Table 152. Beta-Adrenoceptor Agonists Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Beta-Adrenoceptor Agonists
Figure 2. Global Beta-Adrenoceptor Agonists Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Beta-Adrenoceptor Agonists Market Share by Type in 2022 & 2029
Figure 4. β 1 Agonist Product Picture
Figure 5. β 2 Agonists Product Picture
Figure 6. Global Beta-Adrenoceptor Agonists Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Beta-Adrenoceptor Agonists Market Share by Application in 2022 & 2029
Figure 8. Asthma
Figure 9. Anaphylactic Shock
Figure 10. Severe Hypotension
Figure 11. Acute Heart Failure
Figure 12. Acute Renal Failure
Figure 13. Other
Figure 14. Global Beta-Adrenoceptor Agonists Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Beta-Adrenoceptor Agonists Market Size (2018-2029) & (US$ Million)
Figure 16. Global Beta-Adrenoceptor Agonists Sales (2018-2029) & (K Units)
Figure 17. Global Beta-Adrenoceptor Agonists Average Price (US$/Unit) & (2018-2029)
Figure 18. Beta-Adrenoceptor Agonists Report Years Considered
Figure 19. Beta-Adrenoceptor Agonists Sales Share by Manufacturers in 2022
Figure 20. Global Beta-Adrenoceptor Agonists Revenue Share by Manufacturers in 2022
Figure 21. The Global 5 and 10 Largest Beta-Adrenoceptor Agonists Players: Market Share by Revenue in 2022
Figure 22. Beta-Adrenoceptor Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 23. Global Beta-Adrenoceptor Agonists Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 24. North America Beta-Adrenoceptor Agonists Sales Market Share by Country (2018-2029)
Figure 25. North America Beta-Adrenoceptor Agonists Revenue Market Share by Country (2018-2029)
Figure 26. United States Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Canada Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Europe Beta-Adrenoceptor Agonists Sales Market Share by Country (2018-2029)
Figure 29. Europe Beta-Adrenoceptor Agonists Revenue Market Share by Country (2018-2029)
Figure 30. Germany Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. France Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. U.K. Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Italy Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Russia Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Asia Pacific Beta-Adrenoceptor Agonists Sales Market Share by Region (2018-2029)
Figure 36. Asia Pacific Beta-Adrenoceptor Agonists Revenue Market Share by Region (2018-2029)
Figure 37. China Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Japan Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. South Korea Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. India Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Australia Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. China Taiwan Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Southeast Asia Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Beta-Adrenoceptor Agonists Sales Market Share by Country (2018-2029)
Figure 45. Latin America Beta-Adrenoceptor Agonists Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Beta-Adrenoceptor Agonists Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Beta-Adrenoceptor Agonists Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Beta-Adrenoceptor Agonists Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Beta-Adrenoceptor Agonists by Type (2018-2029)
Figure 55. Global Revenue Market Share of Beta-Adrenoceptor Agonists by Type (2018-2029)
Figure 56. Global Beta-Adrenoceptor Agonists Price (US$/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Beta-Adrenoceptor Agonists by Application (2018-2029)
Figure 58. Global Revenue Market Share of Beta-Adrenoceptor Agonists by Application (2018-2029)
Figure 59. Global Beta-Adrenoceptor Agonists Price (US$/Unit) by Application (2018-2029)
Figure 60. Beta-Adrenoceptor Agonists Value Chain
Figure 61. Beta-Adrenoceptor Agonists Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed